NovoCure Limited (NASDAQ:NVCR) Director Sells $204,550.00 in Stock

NovoCure Limited (NASDAQ:NVCR) Director Gabriel Leung sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, June 7th. The stock was sold at an average price of $204.55, for a total transaction of $204,550.00. Following the sale, the director now directly owns 73,045 shares in the company, valued at approximately $14,941,354.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Gabriel Leung also recently made the following trade(s):

  • On Wednesday, May 5th, Gabriel Leung sold 1,000 shares of NovoCure stock. The stock was sold at an average price of $199.67, for a total transaction of $199,670.00.
  • On Tuesday, April 13th, Gabriel Leung sold 6,000 shares of NovoCure stock. The stock was sold at an average price of $198.84, for a total transaction of $1,193,040.00.

Shares of NVCR stock opened at $217.48 on Friday. The company has a fifty day moving average price of $187.26. The company has a quick ratio of 8.94, a current ratio of 9.19 and a debt-to-equity ratio of 1.50. The stock has a market cap of $22.49 billion, a price-to-earnings ratio of 1,977.27 and a beta of 1.08. NovoCure Limited has a fifty-two week low of $55.40 and a fifty-two week high of $220.48.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, April 29th. The medical equipment provider reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.06). NovoCure had a net margin of 2.22% and a return on equity of 3.30%. As a group, equities research analysts predict that NovoCure Limited will post 0.08 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sterling Financial Planning Inc. purchased a new position in shares of NovoCure during the 4th quarter worth $26,000. RWM Asset Management LLC purchased a new position in shares of NovoCure during the 4th quarter worth $35,000. NEXT Financial Group Inc purchased a new position in shares of NovoCure during the 4th quarter worth $35,000. Captrust Financial Advisors raised its holdings in shares of NovoCure by 316.5% during the 1st quarter. Captrust Financial Advisors now owns 354 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 269 shares during the period. Finally, Regent Peak Wealth Advisors LLC purchased a new position in shares of NovoCure during the 4th quarter worth $58,000. Institutional investors and hedge funds own 71.78% of the company’s stock.

A number of research firms recently issued reports on NVCR. Truist lifted their price target on shares of NovoCure from $132.00 to $142.00 in a research note on Monday, April 19th. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Wednesday, May 12th. Northland Securities lifted their price target on shares of NovoCure from $200.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, April 14th. Wedbush reissued an “underperform” rating and issued a $154.00 price target (down previously from $159.00) on shares of NovoCure in a research note on Tuesday, April 20th. Finally, Mizuho lifted their price target on shares of NovoCure from $175.00 to $242.00 and gave the company a “buy” rating in a research note on Wednesday, April 14th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $195.71.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.

Featured Article: Why do companies issue monthly dividends?

Insider Buying and Selling by Quarter for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.